Indaptus Therapeutics, Inc. (INDP) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-03-24

Indaptus Therapeutics, Inc. (INDP) — no SEC Form 4 insider filings recorded in the last 90 days. 5 Form 8-K material event filings were reported by INDP in the last 90 days. InsiderAlpha tracks every INDP SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Indaptus Therapeutics, Inc. (INDP)

SEC CIK	0001857044

90-Day SEC Filing Activity

Form 8-K filings (90d)	5
Latest Form 4 filing	2026-03-24

Recent INDP Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-01-20	Ben-Tzvi Avraham	Director	A — Grant or award	25.0K	$0.00	—	SEC
2025-12-22	Sassi Nir	Chief Financial Officer	A — Grant or award	26.8K	$2.03	$54K	SEC
2025-12-22	Meckler Jeffrey A	Co-Chief Executive Officer	A — Grant or award	216.6K	$2.03	$440K	SEC
2025-12-22	Newman Michael James	CSO and Director	A — Grant or award	52.2K	$2.03	$106K	SEC
2025-12-22	Linscott Walt Addison	Chief Operating Officer	A — Grant or award	54.4K	$2.03	$110K	SEC
2025-07-27	Meckler Jeffrey A	Chief Executive Officer	A — Grant or award	6.1K	$8.30	$50K	SEC
2024-11-25	Meckler Jeffrey A	CEO and Director	A — Grant or award	42.6K	$1.18	$50K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Indaptus Therapeutics, Inc. (INDP). Updated in real time as new filings are submitted to the SEC.

Recent INDP Form 8-K Material Events

2026-06-24 — Item 1.01, 3.02, 9.01 [SEC]
2026-06-05 — Item 5.02, 9.01 [SEC]
2026-05-15 — Item 2.02, 9.01 [SEC]
2026-04-24 — Item 5.02, 9.01 · Leadership · neutral [SEC]
Indaptus Therapeutics appointed two independent directors, Tim Ruan and Dr. Johnny Fox Arrowsmith (formerly Yi Zhang), effective April 22, 2026. This is an amendment filing (8-K/A) that corrects the legal name of one director and provides biographical information on both appointe
2026-04-23 — Item 5.02, 9.01 · Leadership · neutral [SEC]
Indaptus Therapeutics appointed two independent directors to its Board of Directors effective April 22, 2026: Tim Ruan, a financial executive with capital markets and biotech experience currently serving as CFO of Ocumension Therapeutics, and Dr. Yi Zhang, an intellectual propert

Recent Insider Filings

2026-03-24 — Lazar David E. (Director)
2026-02-27 — Jabbour Jerome D (Director)
2026-02-13 — Meckler Jeffrey A (Co-Chief Executive Officer)
2026-01-23 — Ben-Tzvi Avraham (Director)
2026-01-23 — NATAN DAVID (Director)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in INDP insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

INDP Insider Trading — FAQ

What is the latest insider trade for INDP?: Indaptus Therapeutics, Inc. (INDP) had 0 insider filings in the last 90 days, with the most recent on 2026-03-24. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying INDP stock?: 0 insider purchases of INDP were filed in the last 90 days.
How many insiders are selling INDP stock?: 0 insider sales of INDP were filed in the last 90 days.
Where can I see INDP SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every INDP SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live INDP dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.